Special Authority: Empagliflozin and Semaglutide (inj)

  • Version
  • Download 525
  • File Size 361.87 KB
  • File Count 2
  • Create Date January 9, 2023
  • Last Updated January 9, 2023

Special Authority: Empagliflozin and Semaglutide (inj)

Pharmacare now considers SGLT2 and GLP1 (injectable) products as 2nd line diabetes drugs - after Metformin. The attached eFORMS are specific to these products.  Note that approval for a DPP4 product (a separate eFORM needed) cancels approval for either of these and vice versa.

There are two versions - one with a wet signature only (Stan Hurwitz), and one with signature stamp (John Yap) as the default and a wet signature as a back-up option.

Attached Files

Ozempic-SA.zip - wet signature onlyDownload
SA_Empagliflozin_Semaglutide_V1_Jan8_2023-1.zip - signature stamp default; wet signature option availableDownload